Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly

Clinical Interventions in Aging

Volumn 6, Issue 1, 2011, Pages 27-35

  Long, Sydney B ^a   Blaha, Michael J ^a   Blumenthal, Roger S ^a   Michos, Erin D ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Elderly; JUPITER; Risk; Rosuvastatin

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; FLUOROBENZENE; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

AGE; AGED; BLEEDING; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DIET THERAPY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG RESISTANCE; DRUG SAFETY; GASTROINTESTINAL DISEASE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMODIALYSIS; HEMODIALYSIS PATIENT; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; KIDNEY FAILURE; LIVER DISEASE; MULTICENTER STUDY (TOPIC); MUSCLE WEAKNESS; NEOPLASM; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SECONDARY PREVENTION; STROKE; SYSTOLIC HEART FAILURE; UNSTABLE ANGINA PECTORIS; CARDIOVASCULAR DISEASE; RISK FACTOR;

AGED; CARDIOVASCULAR DISEASES; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PYRIMIDINES; RISK FACTORS; RISK REDUCTION BEHAVIOR; SULFONAMIDES;

EID: 80051626920     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S8101     Document Type: Review

References (56)

1. Heart disease and stroke statistics-2010 update. Available at: http://www.americanheart.org/presenter.jhtml?identifierh3018163. Accessed 2010 Nov 22.
2. Gopal A, Budoff MJ. Coronary calcium scanning in geriatric cardiology. Am J Geriatr Cardiol. 2007;16:369-375.
3. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
4. Akosah KO, Schaper A, Cogbill C, et al. Preventing myocardial infarction in the young adult in the first place: How do the National Cholesterol Education Panel III guidelines perform? J Am Coll Cardiol. 2003;41:1475-1479.
5. Michos ED, Nasir K, Braunstein JB, et al. Framingham risk equation underestimates subclinical atherosclerosis risk in asymptomatic women. Atherosclerosis. 2006;184:201-206.
6. DeMazumder D, Hasan RK, Blumenthal RS, Michos ED, Jones S. Should statin therapy be allocated on the basis of global risk or on the basis of randomized trial evidence? Am J Cardiol. 2010;106:905-909.
7. Alexander KP, Newby LK, Cannon CP, et al. Acute coronary care in the elderly, Part I: Non-ST-segment-elevation acute coronary syndromes: A scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology, in collaboration with the Society of Geriatric Cardiology. Circulation. 2007;115:2549-2569.
8. Keller NM, Feit F. Coronary artery disease in the geriatric population. Prog Cardiovasc Dis. 1996;38:407-418.
9. Hanon O. Coronary artery disease in patients 80 years and older. Rev Prat. 2008;58:156-170. French.
10. Davidson MH, Maki KC, Pearson TA, et al. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II Survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol. 2005;96:556-563.
11. Ridker PM, Danielson E, Fonseca FA, et al; for the JUPITER study group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
12. Kapur NK. Rosuvastatin: A highly potent statin for the prevention and management of coronary artery disease. Expert Rev Cardiovasc Ther. 2007;5:161-175.
13. Yildirir A, Muderrisoglu H. Non-lipid effects of statins: Emerging new indications. Curr Vasc Pharmacol. 2004;2:309-318.
14. Jones PH, Davidson MH, Stein EA, et al; STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol. 2003;92:152-160.
15. Schuster H, Barter PJ, Stender S, et al; Effective Reductions in Cholesterol Using Rosuvastatin Therapy I study group. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I). Am Heart J. 2004;147:705-713.
16. Ballantyne CM, Bertolami M, Hernandez Garcia HR, et al. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patient: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapy (MERCURY II). Am Heart J. 2006;151:975. e1-979. e1.
17. Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial. Lancet. 2009;373:1175-1182.
18. LaRosa JC, Grundy SM, Waters DD, et al; for the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
19. Cannon CP, Braunwald E, McCabe CH, et al; for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators (PROVE-IT TIMI 22). Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
20. Pederson TR, Cater NB, Faergeman O, et al. Comparison of atorvastatin 80 mg/day vs simvastatin 20-40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial). Am J Cardiol. 2010;106:354-359.
21. Tzeng TB, Schneck DW, Birmingham BK, et al. Population pharmacokinetics of rosuvastatin: Implications of renal impairment, race, and dyslipidaemia. Curr Med Res Opin. 2008;24:2575-2585.
22. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360-381.
23. The Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
24. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med. 1996;335:1001-1009.
25. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
26. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals a randomized placebo controlled trial. Lancet. 2002;360:7-22.
27. Sheperd J, Blauw GJ, Murphy MB, et al; for the PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomized controlled trial. Lancet. 2002;360:1623-1630.
28. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: Meta-analysis of randomized controlled trials. BMJ. 2009;338:b2376.
29. Deedwania P, Stone PH, Bairey Merz CN, et al. Effect of intensive vs moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: Results of the Study Assessing Goals in the Elderly (SAGE). Circulation. 2007;116:700-707.
30. Gransbo K, Melander O, Wallentin L, et al. Cardiovascular and cancer mortality in very elderly post-myocardial infarction patients receiving statin treatment. J Am Coll Cardiol. 2010;55:1362-1369.
31. Shepherd J, Cobbe SM, Ford I, et al; for the West of Scotland Coronary Prevention Study Group (WOSCOPS). Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
32. Nakamura H, Arakawa K, Itakura H, et al; for the MEGA group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): A prospective randomized controlled trial. Lancet. 2006;368:1155-1163.
33. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of (AFCAPS/TexCAPS) Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-1622.
34. Sever PS, Dahlof B, Poulter NR, et al; for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicenter randomized controlled trial. Lancet. 2003;361:1149-1158.
35. Glynn RJ, Danielson E, Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. 2009;360:1851-1861.
36. Glynn RJ, Koenig W, Nordestgaard BG, Sheperd J, Ridker PM. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low density lipoprotein cholesterol levels: Exploratory analysis of a randomized trial. Ann Intern Med. 2010;152:488-496.
37. Lewington S, Whitlock G, Clarke R, et al. Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex, and blood pressure: A meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370:1829-1839.
38. Narla V, Blaha MJ, Blumenthal RS, Michos ED. The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: Perspectives, outcomes, and consequences. Vasc Health Risk Manag. 2009;5:1033-1042.
39. Bassler D, Briel M, Montori VM, et al. Stopping randomized trials early for benefit and estimation of treatment effects: Systematic review and meta-regression analysis. JAMA. 2010;303:1180-1187.
40. Ridker PM, Glynn RJ. The JUPITER trial: Responding to the critics. Am J Cardiol. 2010;106:1351-1356.
41. Michos ED, Blumenthal RS. Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the US. J Am Coll Cardiol. 2009;53:931-935.
42. Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395-1407.
43. Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk of cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;16:489-495.
44. Kjekshus J, Apetrei E, Barrios V, et al; for the CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248-2261.
45. McMurray JJ, Kjekshus J, Gullestad L, et al; for the CORONA Study Group. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): A retrospective analysis. Circulation. 2009;120:2188-2196.
46. Lorgelly PK, Briggs AH, Wedel H, et al; for the CORONA Study Group. An economic evaluation of rosuvastatin treatment in systolic heart failure: Evidence from the CORONA trial. Eur J Heart Fail. 2010;12:66-74.
47. Lemaitre RN, Furberg CD, Newman AB, et al. Time trends in the use of cholesterol-lowering agents in older adults: The Cardiovascular Health Study. Arch Intern Med. 1998;158:1761-1768.
48. Whincup PH, Emberson JR, Lennon L, Walker M, Papacosta O, Thomson A. Low prevalence of lipid lowering drug use in older men with established coronary heart disease. Heart. 2002;88:25-29.
49. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high risk elderly patients: The treatment-risk paradox. JAMA. 2004;291:1864-1870.
50. Gnavi R, Migliardi A, Demaria M, Petrelli A, Caprioglio A, Costa G. Statins prescribing for the secondary prevention of ischaemic heart disease in Torino, Italy. A case of ageism and social inequalities. Eur J Public Health. 2007;17:492-496.
51. Niska R, Han B. Statins for secondary cardiovascular disease prevention for older primary care patients. J Natl Med Assoc. 2009;101:705-710.
52. Krumholz HM, Murillo JE, Chen J, et al. Thrombolytic therapy for eligible elderly patients with acute myocardial infarction. JAMA. 1997;277:1683-1688.
53. Rochon PA, Anderson GM, Tu JV, et al. Use of beta-blocker therapy in older patients after acute myocardial infarction in Ontario. CMAJ. 1999;161:1403-1408.
54. Sattar N, Preiss D, Murray HM, et al. Statins and the risk of incident diabetes: A collaborative meta-analysis of randomized statin trials. Lancet. 2010;375:735-742.
55. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Lipid-lowering agents and new onset diabetes mellitus. Expert Opin Pharmacother. 2010;11:1965-1970.
56. Robinson JG, Bakris G, Torner J, Stone NJ, Wallace R. Is it time for a cardiovascular primary prevention trial in the elderly? Stroke. 2007;38:441-450.